XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. is a clinical-stage biotech company focused on developing pharmaceutical products for the treatment of autoimmune diseases, particularly lupus. The company's lead drug candidate, hCDR1, is a promising asset for the treatment of systemic lupus erythematosus (SLE). This is significant as current treatments for SLE are often ineffective and can have significant side effects, leaving a gap in the market for more effective and well-tolerated alternatives. With robust clinical data gathered from three clinical trials involving 400 patients and over 200 preclinical studies, XTL Biopharmaceuticals is positioned as a key player in the pursuit of addressing the unmet medical needs for SLE patients. Founded in 1993 and headquartered in Israel, the company is operating in the Biotechnology, Pharmaceutical, and Platforms industries. XTL Biopharmaceuticals secured a $2.80M post-IPO equity investment on 07 March 2017, showcasing investor confidence in the company and its potential for growth and success in the biopharmaceutical space. With its focus on addressing critical medical needs in the autoimmune disease space and promising clinical results, XTL Biopharmaceuticals presents a compelling opportunity for venture capital investment in the biotech sector.